The hematopathological basis for studying effects of the demethylating agent 5-aza-2′-deoxycytidine (decitabine) in myelodysplasia

Annals of Hematology, Supplement

Volumn 84, Issue 13, 2005, Pages 67-79

  Schaefer, Hans Eckart ^a   Lübbert, Michael ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Cytogenetics; DNA methylation; Dysmegakaryocytopoiesis; Enzyme cytochemistry; Immunohistochemistry; MDS

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; PROTEIN P15; CD34 ANTIGEN; MYELOPEROXIDASE; SIDEROPHORE; CYCLIN DEPENDENT KINASE INHIBITOR 2B; DNA; ANTINEOPLASTIC ANTIMETABOLITE; DNA METHYLTRANSFERASE; DRUG DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APLASTIC ANEMIA; BONE MARROW BIOPSY; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DNA METHYLATION; DRUG TARGETING; GENE ACTIVATION; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; RELIABILITY; REVIEW; RISK ASSESSMENT; ALPHA THALASSEMIA; BLOOD CELL COUNT; BLOOD EXAMINATION; CANCER CLASSIFICATION; CYTOCHEMISTRY; CYTOGENETICS; DRUG MECHANISM; DYSERYTHROPOIESIS; GENE TARGETING; HEMATOLOGICAL PARAMETERS; MEGAKARYOCYTE; MYELOBLAST; MYELODYSPLASIA; PERIODIC ACID SCHIFF STAIN; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; SCLEREDEMA; SCORING SYSTEM; ARTICLE; BLOOD ANALYSIS; CHROMOSOME ANALYSIS; CYTOPATHOLOGY; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REPEATED DRUG DOSE; WORLD HEALTH ORGANIZATION; BONE MARROW EXAMINATION; CELL DIFFERENTIATION; CLASSIFICATION; DRUG ANTAGONISM; DRUG EFFECT; PATHOLOGY;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; BONE MARROW EXAMINATION; CELL DIFFERENTIATION; DNA METHYLATION; DNA MODIFICATION METHYLASES; HUMANS; MYELODYSPLASTIC SYNDROMES;

EID: 29144443496     PISSN: 09458077     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-005-0034-8     Document Type: Review

References (50)

1. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189-199 6952920
2. Bennett JM (2000) World Health Organization classification of the acute leukemias and myelodysplastic syndrome. Int J Hematol 72:131-133 11039659
3. van den Berghe H, Cassiman J-J, David G, Fryns J-P, Michaux J-L, Sokal G (1974) Distinct haematological disorder with deletion of long arm of No. 5 chromosome. Nature 251:437-438 10.1038/251437a0
4. M Bessis 1977 Blood smears reinterpreted Springer Berlin Heidelberg New York
5. van den Bosch J, Lübbert M, Verhoef G, Wijermans PW (2004) The effects of 5-aza-2′-deoxycytidine (decitabine) on the platelet count in patients with inter-mediate and high-risk myelodysplastic syndromes. Leuk Res 28:785-790 10.1016/j.leukres.2003.11.016
6. Bowen D, Culligan D, Jowitt S, Kelsey S, Mufti G, Oscier D, Parker J; UK MDS Guidelines Group (2003) Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol 120:187-200 10.1046/ j.1365-2141.2003.03907.x
7. GL Castoldi 2003 The myelodysplastic syndromes In: D Zucker-Franklin CE Grossi (eds) An atlas of blood cells, function and pathology 3rd edn. Edi-Ermes Milan
8. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, Löwenberg B, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Wijermans PW, Gore S, Greenberg PL (2000) World Health Organization (WHO) International Working Group. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96:3671-3674 11090046
9. Cheson BD, Bennett JM, Kantarjian H, Schiffer CA, Nimer SD, Löwenberg B, Stone RM, Mittelman M, Sanz GF, Wijermans PW, Greenberg PL (2001) Myelodysplastic syndromes standardized response criteria; further definition. Blood 98:1985 10.1182/blood.V98.6.1985
10. Claus R, Almstedt M, Lübbert M (2005) Epigenetic treatment of hematopoietic malignancies: In vivo targets of demethylating agents. Semin Oncol 32:511-520 10.1053/j.seminoncol.2005.07.024
11. Daskalakis M, Nguyen TT, Nguyen C, Guldberg P, Köhler G, Wijermans P, Jones PA, Lübbert M (2002) Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2′-deoxycytidine (decitabine) treatment. Blood 100:2957-2964 10.1182/blood.V100.8.2957
12. Davis AT, Brunning RD, Quie PG (1971) Polymorphonuclear leukocyte myeloperoxidase deficiency in a patient with myelomonocytic leukemia. N Engl J Med 285:789-790 4935938
13. Gassmann W (2004) Morphological leukemia diagnostics in the competence net for acute and chronic leukemias. Med Welt 55:256-260
14. Gattermann N, Retzlaff S, Wang YL, Hofhaus G, Heinisch J, Aul C, Schneider W (1997) Heteroplasmic point mutations of mitochondrial DNA affecting subunit I of cytochrome c oxidase in two patients with acquired idiopathic sideroblastic anemia. Blood 90:4961-4972 9389715
15. Germing U, Gattermann N, Strupp C, Aivado M, Aul C (2000) Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: A retrospective analysis of 1600 patients. Leuk Res 24:983-992 10.1016/S0145-2126(00)00088-6
16. Germing U, Gattermann N (2001) Refractory anemia with excess of blasts in transformation: A dying category? Leuk Res 25:1095-1096 10.1016/ S0145-2126(01)00080-7
17. Giagounidis AA, Germing U, Haase D, Hildebrandt B, Schlegelberger B, Schoch C, Wilkens L, Heinsch M, Willems H, Aivado M, Aul C (2004) Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia 18:113-119 10.1038/sj.leu.2403189
18. Greenberg P, Cox C, Le Beau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088 9058730
19. Greenberg P, Anderson J, de Witte T, Estey E, Fenaux P, Gupta P, Hamblin T, Hellström-Lindberg E, List A, Mufti G, Neuwirtova R, Ohyashiki K, Oscier D, Sanz G, Sanz M, Willman C (2000) Problematic WHO reclassification of myelodysplastic syndromes. Members of the International MDS Study Group. J Clin Oncol 18:3447-3452 11013289
20. Gupta R, Abdalla SH, Bain BJ (1999) Thrombocytosis with sideroblastic erythropoiesis: A mixed myeloproliferative myelodysplastic syndrome. Leuk Lymphoma 34:615-619 10492088
21. Herman JG, Baylin SB (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349:2042-2054 10.1056/ NEJMra023075
22. Hofmann WK, Lübbert M, Hoelzer D, Koeffler HP (2004) Myelodysplastic syndromes. Hematol J 5:1-8 10.1038/sj.thj.6200335
23. Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, Bayar E, Lyons J, Rosenfeld CS, Cortes J, Kantarjian HM (2004) Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103:1635-1640 10.1182/blood-2003-03-0687
24. Jaffe ES, Lee Harris N, Stein H, Vardiman JW (eds) (2001) Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC, Lyon
25. Juneja SK, Imbert M, Jouault H, Scoazec JY, Sigaux F, Sultan C (1983) Haematological features of primary myelodysplastic syndromes (PMDS) at initial presentation: A study of 118 cases. J Clin Pathol 36:1129-1135 6619310
26. Koike T, Uesugi Y, Toba K, Narita M, Fuse I, Takahashi M, Shibata A (1995) 5q-minus-syndrome presenting as essential thrombocythemia myelodysplastic syndrome or chronic myeloproliferative disorders? Leukemia 9:517-518 7885050
27. List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, Rimsza L, Heaton R, Knight R, Zeldis JB (2005) Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352:549-557 10.1056/NEJMoa041668
28. H Löffler J Rastetter T Haferlach 2004 Atlas der klinischen Hämatologie 6th edn. Springer Berlin Heidelberg New York
29. Lübbert M, Wijermans PW, Kunzmann R, Verhoef G, Bosly A, Ravoet C, Andre M, Ferrant A (2001) Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidine. Br J Haematol 114:349-357 10.1046/j.1365-2141.2001.02933.x
30. Mahmood T, Robinson WA, Hamstra RD, Wallner SF (1979) Macrocytic anemia, thrombocytosis and nonlobulated megakaryocytes in the 5q- syndrome, a distinct entity. Am J Med 66:946-950 10.1016/0002-9343(79)90449-2
31. GJ Mufti J Flandrin HE Schaefer AA Sandberg EJ Kanfer 1996 An atlas of malignant haematology. Cytology, histology and cytogenetics Dunitz London
32. Murphy S (1993) Thrombocytosis and thrombocythaemia. Clin Haematol 12:89-106
33. O Naegeli 1931 Blutkrankheiten und Blutdiagnostik 5th edn. Leipzig Veit & Co. Berlin 1907-1908
34. Nagai K, Kohno T, Chen YX, Tsushima H, Mori H, Nakamura H, Jinnai I, Matsuo T, Kuriyama K, Tomonaga M, Bennett JM (1996) Diagnostic criteria for hypocellular acute leukemia, a clinical entity distinct from overt acute leukemia and myelodysplastic syndrome. Leuk Res 20:563-574 10.1016/ 0145-2126(95)00136-0
35. Schaefer HE (1990) Zytologische Hämatopathologie unter besonderer Berücksichtigung histochemischer Methoden. Beitr Onkol 38:196-260
36. HE Schaefer 2005 Die histologische Diagnostik an Beckenkammbiopsien In: T Haferlach (ed) Labordiagnostik bei Leukämien und Lymphomen UNI-MED Bremen 32-72
37. Schaefer HE, Fischer R (1970) Peroxydaseaktivität als Ursache der stabilen Sudanophilie in Granulozyten. Klin Wochenschr 48:1424-1425 10.1007/BF01488819
38. Schaefer HE, Weller P, Lansch D (1983) Erworbene und ererbte Defektformen der granulozytären Peroxidase (POX). Acta Histochem 28:219-234
39. Schmalzl F, Lederer B, Braunsteiner H (1970) Atypical myeloblastic leukemia with differentiation into "paraneutrophils". Blut (Berl) 20:337-349
40. Schmalzl F, Wiedemann C (1983) Zur Technik quantitativer enzymzytochemischer Untersuchungen an polymorphkernigen Neutrophilen des Menschen. Acta Histochem 28:157-162
41. Swolin B, Weinfeld A, Ridell B, Waldenström J, Westin J (1981) On the 5q- deletion: Clinical and cytogenetic observations in ten patients and review of the literature. Blood 58:986-993 6945880
42. Steensma DP, Gibbons RJ, Higgs DR (2005) Acquired alpha-thalassemia in association with myelodysplastic syndrome and other hematologic malignancies. Blood 105:443-52 10.1182/blood-2004-07-2792
43. Thiele J, Schmitz B, Gross H, Kvasnicka HM, Niederle N, Leder LD, Fischer R (1997) Fluorescence in situ hybridization (FISH) reveals that in chronic myelogenous leukaemia (CML) following interferon alpha therapy, normalization of megakaryocyte size is associated with the loss of bcr/abl translocation. Histopathology 31:215-221 10.1046/ j.1365-2559.1997.2480853.x
44. Wells DA, Benesch M, Loken MR, Vallejo C, Myerson D, Leisenring WM, Deeg HJ (2003) Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood 102:394-403 10.1182/blood-2002-09-2768
45. Wheeler LA, Hogan RP 3rd, Schwenk GR Jr, Griep JA (1983) Multinucleate megakaryocytes in refractory anemia with excess blasts. Arch Pathol Lab Med 107:277-278
46. Wijermans PW, Krulder JW, Huijgens PC, Neve P (1997) Continuous infusion of low-dose 5-aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia 11:1-5 10.1038/ sj.leu.2400526
47. Wijermans P, Lübbert M, Verhoef G, Bosly A, Ravoet C, Andre M, Ferrant A (2000) Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: A multicenter phase II study in elderly patients. J Clin Oncol 18:956-962 10694544
48. Wijermans PW, Lübbert M, Verhoef G, Klimek V, Bosly A (2005) An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients. Ann Hematol. DOI 10.1007/s00277-005-0012-1
49. D Zucker-Franklin 2003 Megakaryocytes and platelets In: D Zucker-Franklin CE Grossi (ed) An atlas of blood cells, function and pathology 3rd edn. Edi-Ermes Milan
50. http://www.leukemia-net.org/